Hunting growth, Samsung races to get up to speed on biosimilar drugs

SEOUL, June 7 (Reuters) - As Samsung Bioepis raced to be first to market with a copy of Enbrel, a blockbuster rheumatoid arthritis drug, countdown clocks reminded workers - heading for lunch, meetings or even the washroom - of the days to the first mass production run.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.